Liquidia Co. (NASDAQ:LQDA) Receives $24.67 Consensus Target Price from Analysts

Liquidia Co. (NASDAQ:LQDA) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $24.67.

LQDA has been the subject of several research analyst reports. Raymond James raised Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. BTIG Research decreased their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a report on Monday, August 19th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a report on Monday, August 19th. Scotiabank initiated coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Finally, Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective for the company.

Insider Transactions at Liquidia

In other news, General Counsel Russell Schundler sold 2,576 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $28,619.36. Following the completion of the sale, the general counsel now owns 486,048 shares in the company, valued at $5,399,993.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Liquidia news, Director Caligan Partners Lp acquired 150,000 shares of the business’s stock in a transaction on Friday, August 30th. The stock was purchased at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the transaction, the director now owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Russell Schundler sold 2,576 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the completion of the transaction, the general counsel now owns 486,048 shares of the company’s stock, valued at $5,399,993.28. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock worth $236,021 over the last 90 days. 31.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Patient Square Capital LP purchased a new position in Liquidia in the first quarter worth $105,942,000. Vanguard Group Inc. increased its position in shares of Liquidia by 1.5% in the first quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after buying an additional 43,352 shares in the last quarter. Farallon Capital Management LLC purchased a new position in shares of Liquidia in the first quarter valued at $30,311,000. Whitefort Capital Management LP increased its position in shares of Liquidia by 45.8% in the first quarter. Whitefort Capital Management LP now owns 337,607 shares of the company’s stock valued at $4,980,000 after buying an additional 106,049 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Liquidia by 119.4% in the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after buying an additional 125,315 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Down 0.3 %

Shares of LQDA opened at $11.01 on Monday. The stock has a 50 day moving average price of $10.23 and a 200 day moving average price of $11.70. The company has a market capitalization of $845.50 million, a price-to-earnings ratio of -7.06 and a beta of 0.22. Liquidia has a 52-week low of $6.06 and a 52-week high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. On average, equities analysts anticipate that Liquidia will post -1.69 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).